Megakaryocytes in myeloproliferative neoplasms have unique somatic mutations

Belinda B. Guo, Richard J. Allcock, Bob Mirzai, Jacques A. Malherbe, Fizzah A. Choudry, Mattia Frontini, Hun Chuah, James Liang, Simon E. Kavanagh, Rebecca Howman, Willem H. Ouwehand, Kathryn A. Fuller, Wendy Erber

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Myeloproliferative neoplasms (MPNs) are a group of related clonal hemopoietic stem cell disorders associated with hyperproliferation of myeloid cells. They are driven by mutations in the hemopoietic stem cell, most notably JAK2V617F, CALR, and MPL. Clinically, they have the propensity to progress to myelofibrosis and transform to acute myeloid leukemia. Megakaryocytic hyperplasia with abnormal features are characteristic, and it is thought that these cells stimulate and drive fibrotic progression. The biological defects underpinning this remain to be explained. In this study we examined the megakaryocyte genome in 12 patients with MPNs to determine whether there are somatic variants and whether there is any association with marrow fibrosis. We performed targeted next-generation sequencing for 120 genes associated with myeloid neoplasms on megakaryocytes isolated from aspirated bone marrow. Ten of the 12 patients had genomic defects in megakaryocytes that were not present in nonmegakaryocytic hemopoietic marrow cells from the same patient. The greatest allelic burden was in patients with increased reticulin deposition. The megakaryocyte-unique mutations were predominantly in genes that regulate chromatin remodeling, chromosome alignment, and stability. These findings show that genomic abnormalities are present in megakaryocytes in MPNs and that these appear to be associated with progression to bone marrow fibrosis.
Original languageEnglish
Pages (from-to)1512–1522
Number of pages11
JournalThe American Journal of Pathology
Issue number7
Publication statusPublished - Jul 2017


Dive into the research topics of 'Megakaryocytes in myeloproliferative neoplasms have unique somatic mutations'. Together they form a unique fingerprint.

Cite this